Pancreatic cancer trials recruiting in Tennessee

All Pancreatic cancer trials nationally

Cities in Tennessee

Recruiting trials in Tennessee

• A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
  NCT05932862 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Germantown, Nashville
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
  NCT07644559 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
  NCT06695845 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Knoxville, Nashville
• A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  NCT03394365 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · Tennessee: Memphis, Nashville
• A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
  NCT06906562 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Knoxville, Memphis, Nashville
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Chattanooga, Memphis, Nashville
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
  NCT07277413 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
  NCT07066657 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
  NCT05877599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of PHN-012 in Patients With Advanced Solid Tumors
  NCT07127874 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
  NCT06914128 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors
  NCT04389632 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
  NCT07522073 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
  NCT06179160 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
  NCT05941507 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Chattanooga, Germantown, Nashville
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
  NCT06051695 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
  NCT06835569 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
  NCT07090499 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
  NCT06760819 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
  NCT04503265 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
  NCT04678648 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
  NCT07094113 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
  NCT04858334 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Collierville, Memphis
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07562152 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Germantown, Nashville
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
  NCT04924075 · Phase: Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Tennessee: Nashville
• CT-95 in Advanced Cancers Associated With Mesothelin Expression
  NCT06756035 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Tennessee: Germantown
• Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
  NCT04239573 · Phase: Not specified · Ages: 50 Years to 75 Years · Sex: All (male and female) · Tennessee: Knoxville, Memphis, Nashville
• DESTINY-PANTUMOUR04
  NCT07124000 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: All (male and female) · Tennessee: Nashville
• Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
  NCT04588025 · Phase: Not applicable (e.g. observational or device study) · Ages: 19 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
  NCT06239194 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Familial Investigations of Childhood Cancer Predisposition
  NCT03050268 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Tennessee: Memphis
• Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
  NCT00899626 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Increasing Germline Genetic Testing for Patients With Cancer
  NCT07307664 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · Tennessee: Nashville
• Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
  NCT03257033 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
  NCT06026410 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
  NCT06807437 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Knoxville, Memphis
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Pancreatic Cancer Early Detection Consortium
  NCT04970056 · Phase: Not specified · Ages: 18 Years to 90 Years · Sex: All (male and female) · Tennessee: Knoxville
• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
  NCT06218914 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
  NCT01885299 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Tennessee: Chattanooga
• Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07259317 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Tennessee: Memphis, Nashville
• Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
  NCT06937177 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Memphis, Nashville
• Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
  NCT05732831 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
  NCT04981119 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
  NCT04195347 · Phase: Phase 1, Phase 2 · Ages: Up to 21 Years · Sex: All (male and female) · Tennessee: Memphis
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
  NCT07252232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
  NCT06128551 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
  NCT05254171 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
  NCT06545942 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
  NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Chattanooga, Nashville
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06040541 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
  NCT05477576 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
  NCT07165132 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
  NCT04429542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
  NCT04900818 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
  NCT06084481 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
  NCT06998940 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Collierville, Memphis
• Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
  NCT06016855 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  NCT04851119 · Phase: Phase 1, Phase 2 · Ages: 12 Months to 30 Years · Sex: All (male and female) · Tennessee: Memphis
• Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
  NCT06958328 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Collierville, Memphis
• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
  NCT04172532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Nashville
• Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
  NCT05040360 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Alcoa, Collierville, Knoxville, Memphis
• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
  NCT06943755 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Tennessee: Knoxville, Nashville
• cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
  NCT05366881 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · Tennessee: Memphis, Nashville